Log in

Relevant bibliographies by topics / Low dose tamsulosin

Contents

Journal articles

Academic literature on the topic 'Low dose tamsulosin'

Author: Grafiati

Published: 3 June 2025

Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Low dose tamsulosin.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Low dose tamsulosin"

1

Dr., Taimoor Ahmed Jataoi Dr. Adeel Mahesar Dr. Javed Altaf Jat *. and Dr. Muhammad Ayyaz. "THE AGE DISTRIBUTION AND EFFECTIVENESS OF LOW DOSE TAMSULOSIN IN LOWER URETERIC STONES." Indo American Journal of Pharmaceutical Sciences 04, no. 11 (2017): 4386–90. https://doi.org/10.5281/zenodo.1064351.

Full text

Abstract:

Objective: To determine the effectiveness of low dose tamsulosin as a medical expulsive therapy in patients with lower ureteric stones. Patients and Methods: The six months randomized control trial was conducted on all patients with either gender, age range 30-60 years and stone size 4-10 mm in the lower 1/3rd of the ureter determined on ultrasound at tertiary care hospital. Group A patients was offered low dose tamsulosin (0.2 mg) one tablet daily in the morning for a maximum of 4 weeks and group B served as control. The final outcome was measured at the end of 4th week of treatment. Patients

APA, Harvard, Vancouver, ISO, and other styles

2

Arka Banerjee, Pranab Kumar Ghosh, and Hindol Mondal. "Role of low-dose deflazacort with tamsulosin versus tamsulosin alone for medical expulsive therapy of ureteric stone." Asian Journal of Medical Sciences 15, no. 7 (2024): 177–81. http://dx.doi.org/10.3126/ajms.v15i7.65415.

Full text

Abstract:

Background: Urolithiasis is a common condition in daily urological practice. Medical Expulsive Therapy (MET) is non-invasive approach for removal of ureteric stone. In MET, alpha-blocker Tamsulosin is commonly used in treating urolithiasis but it does not address the pathology of inflammation presents in such condition. With addition of low dose Deflazacort as anti-inflammatory agent, there may have a potential to improve the pathology and outcome of the treatment. Aims and Objectives: This study aims to find the efficacy of low-dose deflazacort combined with tamsulosin in the MET for distal u

APA, Harvard, Vancouver, ISO, and other styles

3

Lee, Mary. "Tamsulosin for the Treatment of Benign Prostatic Hypertrophy." Annals of Pharmacotherapy 34, no. 2 (2000): 188–99. http://dx.doi.org/10.1345/aph.18263.

Full text

Abstract:

OBJECTIVE: To review the information necessary to assess the efficacy and safety of tamsulosin compared with other adrenergic antagonists for treatment of symptomatic benign prostatic hyperplasia. DATA SOURCES: A search was conducted of Cumulated Index Medicus, January 1993–August 1999, which was restricted to human trials and English-language journals. STUDYSELECTION AND DATAEXTRACTION: Efficacy studies were included if the design was randomized and included a control group. Drug safety was assessed using data from any patient series or controlled study. DATA SYNTHESIS: Tamsulosin, a uroselec

APA, Harvard, Vancouver, ISO, and other styles

4

Mohamed, G. Soliman Ahmed A. Al-Khalifah Ali H. Al-Khalifah Ali R. Al-Amer Ali S. Al-Badan 6brahim F. Mutaki. "CAN EJACULATORY DYSFUNCTION BE RECOVERED BY LOW DOSE TAMSULOSIN WHILE TREATING SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA?" INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES o6, no. 02 (2019): 3813–17. https://doi.org/10.5281/zenodo.2563927.

Full text

Abstract:

<strong><em>Purpose: </em></strong><em>To evaluate the use of low dose Tamsulosin in relieving lower urinary tract symptoms related to benign prostatic symptoms as a tr</em><em>ial</em><em> to increase the drug safety ( in terms of reducing the drug full dose side effects especially retrograde ejaculation) while maintaining its efficacy in relieving the patients' symptoms. <strong>Material and Methods: </strong>This Prospective study was conducted in King Faisal University polyclinic between November 2013 and March 2014. Patients enrolled in this study were suffering from Lower urinary tra

APA, Harvard, Vancouver, ISO, and other styles

5

Dikko, M., and Y. Sarkingobir. "Body Weight Determination and Histological Examination of Livers in Normal Rats Administered with Tamsulosin." Journal of Applied Sciences and Environmental Management 24, no. 8 (2020): 1335–40. http://dx.doi.org/10.4314/jasem.v24i8.5.

Full text

Abstract:

The objective of this study was to investigate histopathology of livers and carry out body weight determination in normal rats administered with tamsulosin. Standard methods and procedures were used in this study. The results were revealed. Pertaining weight, at the 3rd , 6th and 8th weeks of the study, no significant difference (P>0.05) in weight was found in the group of rats treated with carvedilol (positive control), tamsulosin low dose (12μg/kg) and high dose tamsulosin (40μg/kg) compared to normal control group, respectively. Other inter-groups comparisons were not significantly diffe

APA, Harvard, Vancouver, ISO, and other styles

6

Modi, Jenish, Vipul Lad, and Parag Godhani. "Efficacy of Low-Dose Deflazacort with Tamsulosin in the Medical Expulsive Therapy of Distal Ureterolithiasis: A Randomized Controlled Trial." National Journal of Medical Research 14, no. 04 (2024): 103–8. http://dx.doi.org/10.55489/njmr.140420241011.

Full text

Abstract:

Introduction: Distal ureterolithiasis, characterized by stones in the lower ureter, poses significant challenges in clinical management. Medical expulsive therapy (MET) using Tamsulosin is a common non-invasive treatment, but its efficacy can be limited, especially for stones larger than 5 mm. Deflazacort, a corticosteroid with anti-inflammatory properties, may enhance the effectiveness of Tamsulosin by reducing ureteral inflammation and facilitating stone passage. Methods: This prospective, randomized controlled trial enrolled 80 patients with distal ureteral stones <8 mm. Participants wer

APA, Harvard, Vancouver, ISO, and other styles

7

Rahman, Shafiqur, Mohammad Abdul Aziz, Atm Mowladad Chowdhury, Bakhtiar Ahmed, and Mirza Mahbubul Hasan. "Efficacy of Low Daily Dose of Tadalafil as Mono-Therapy for Diabetic Patients With Lower Urinary Tract Symptoms Suggestive of Benign Enlargement of Prostate." Bangladesh Journal of Urology 20, no. 1 (2020): 18–25. http://dx.doi.org/10.3329/bju.v20i1.49602.

Full text

Abstract:

Objective: To assess efficacy of tadalafil or tamsulosin versus placebo for LUTS/BEP. Methods: This was a triple blind randomized control trial (RCT). This study was done on 150 cases of well controlled diabetic patients with LUTS/BEP after screening. The patients were >45 years of age, international prostate symptom score (IPSS) > 13, maximum urine flow rate (Qmax) 10-15 ml/sec. Selected patients were randomized in to 1:1:1 ratio to once-daily tadalafil 5 mg, tamsulosin 0.4 mg, or placebo for 12 weeks. Efficacy measures were assessed by IPSS, Qmax, post-voidal residue (PVR) in ultra-son

APA, Harvard, Vancouver, ISO, and other styles

8

Tareq, AHM Imrul, and Md Sayedul Islam. "To Compare the Efficacy of Tamsulosin, Solifenacin and Combination of Both in the Treatment of Double-J Stent Related Irritative Lower Urinary Tract Symptoms and Low Back Pain." Bangladesh Journal of Urology 23, no. 1 (2020): 48–51. http://dx.doi.org/10.3329/bju.v23i1.50289.

Full text

Abstract:

Background: Stent-associated symptoms can have a significant impact on patient quality of life. Hematuria, urgency, frequency, dysuria, and both bladder and flank pain are the most prevalent symptoms related to indwelling ureteral stents. Among them irritative lower urinary tract symptoms and low back pain are more frequent. Despite the stent related symptoms, because of its importance stent is being kept in situ with varieties of medication. Several alpha-adrenergic blocker and antimuscarinic drugs are used to relief these symptoms like Tamsulosin, Solifenacin, Alphazosin etc. Both Tamsulosin

APA, Harvard, Vancouver, ISO, and other styles

9

Saito, T., T. Minagawa, T. Ogawa, and O. Ishizuka. "Efficacy of tadalafil against lower urinary tract symptoms after low-dose-rate brachytherapy in prostate cancer patients." Journal of Clinical Urology 12, no. 3 (2018): 223–27. http://dx.doi.org/10.1177/2051415818817127.

Full text

Abstract:

Objectives: This study was performed to evaluate the effects of addition of tadalafil to tamsulosin in the treatment of brachytherapy patients with lower urinary tract symptoms (LUTS). Methods: Localized prostate cancer patients who developed LUTS after low-dose-rate brachytherapy (LDR-BT) were first treated with alpha-1 blockers (tamsulosin, 0.2 mg per day). Those still suffering from LUTS were additionally treated with phosphodiesterase type 5 inhibitor (tadalafil, 5 mg/day). LUTS was evaluated by the International Prostate Symptom Score (IPSS), IPSS Quality of Life (QOL) score, Overactive B

APA, Harvard, Vancouver, ISO, and other styles

10

Watanabe, Masaki, Satoshi Yamaguchi, Hidehiro Kakizaki, Naoki Hirabayashi, and Hironori Ishida. "Evaluation of Alpha 1 Adrenoceptor Antagonist Dose Increase Therapy: An Essential Strategy for Patients with Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia." Current Urology 14, no. 3 (2020): 113–21. http://dx.doi.org/10.1159/000499250.

Full text

Abstract:

<b><i>Introduction</i></b>: There have been a number of reports on dose increase therapy (DI-T) with the alpha 1 adrenoceptor antagonists (α1-blockers) naftopidil and tamsulosin for lower urinary tract symptoms associated with benign prostatic hyperplasia. <b><i>Methods and Results</i></b>: The reports on DI-T (naftopidil 75 mg/d, tamsulosin 0.4 mg/d) in non-responders to low-dose initial therapy (LI-T, naftopidil 50 mg/d, tamsulosin 0.2 mg/d) were summarized. In each study, a non-responder was defined as a patient without sufficient improvements

APA, Harvard, Vancouver, ISO, and other styles

More sources

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!